The ReceptivaDxTM Test is performed on an endometrial biopsy sample, a routine procedure that can be performed during a normal office visit with your Ob-Gyn or Reproductive Specialist. Once collected, the sample is placed in a preservative and sent to our testing facility in Greenville, South Carolina. Once in the lab, biopsies are processed and evaluated by our pathology team. A full pathology report is then prepared and submitted to your physician. Results are usually available in 7-10 days.

In simplest terms, BCL6 is a marker for endometriosis. If the BCL6 marker is found to be elevated in a sample taken from an endometrial biopsy, the patient's inability to become pregnant is likely due to undetected endometriosis interfering with the ability of a fertilized egg to implant. Endometriosis can block successful implantation in both sexual intercourse and in vitro fertilization. While many patients hear about endometriosis in women who have experienced pelvic pain, painful intercourse or heavy bleeding during menses, milder forms without symptoms can be present without experiencing any physical symptoms. These milder forms of endometriosis are often undetectable and cannot always be visualized through ultrasound or laparoscopy. This is the power and benefit to patients by having the ReceptivaDxTM test performed.

If found to be positive for BCL6, a treatment plan involving hormone therapy or laparoscopy to remove visible endometriosis can correct the situation. Patients undergoing 60 days of hormone therapy have shown excellent progress in achieving pregnancy in recent studies.

Receptiva is the only approved and fully licensed test in the US to measure the BCL6 marker in endometrial biopsy samples. We encourage you to download our Receptiva Information Sheet and and discuss it with your physician.

For patients interested in being tested, please fill out the patient form below and our staff will send your physician our ReceptivaDxTM Collection Kit with all the information necessary to properly collect and submit a sample. All samples must be submitted in an approved collection kit. All requests for ReceptivaDxTM require payment via credit card at the time of sample submission. Patients may also pre-pay through our website in advance of their doctor visit.

Dr. Aimee
San Ramon, CA

“I was one of the early adopters of the ReceptivaDx test. Our experience has exceeded my expectations. We can now identify and treat women with early endometriosis who might have gone undetected before. For our patients, this has led to improved success rates, reduced costs and the avoidance of multiple IVF cycles. “
Subscribe to our newsletter and stay up to date with ReceptivaDx.
The ReceptivaDxTM Test was developed by CiceroDx in conjunction with Pathology Consultants, Inc. of Greenville, SC. Pathology Consultants, Inc. is a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). As with other laboratory-developed tests, this testing service has not been cleared or approved by the US FDA or any other federal regulatory agencies. Data have not been submitted to or evaluated by Federal regulatory agencies and the test is not for sale as an In Vitro Diagnostic (IVD) in the US or the EU.
© 2017 Receptivadx. All Rights Reserved